The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 8 June 2004, www.theannals.com, DOI 10.1345/aph.1D391.
 The Annals of Pharmacotherapy: Vol. 38, No. 7, pp. 1286-1292. DOI 10.1345/aph.1D391
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kendrach, M. G
Right arrow Articles by Kelly-Freeman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kendrach, M. G
Right arrow Articles by Kelly-Freeman, M.

DRUG INFORMATION ROUNDS

Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs

Michael G Kendrach, PharmD

Associate Professor, Department of Pharmacy Practice; Director, Samford University Global Drug Information Service, McWhorter School of Pharmacy, Samford University, Birmingham, AL

Maisha Kelly-Freeman, PharmD

Assistant Professor, Department of Pharmacy Practice; Drug Information Specialist, Samford University Global Drug Information Service, McWhorter School of Pharmacy, Samford University

Reprints: Michael G Kendrach PharmD, McWhorter School of Pharmacy, Samford University, 800 Lakeshore Dr., Birmingham, AL 35229-7027, fax 205/726-4012, mgkendra{at}samford.edu

OBJECTIVE: To estimate approximate doses of rosuvastatin equivalent to the other hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) for a temporary substitution program.

DATA SOURCES: A literature search was conducted to locate clinical trials directly comparing rosuvastatin with other statins that evaluated the magnitude of cholesterol lowering.

DATA SYNTHESIS: The mean low-density lipoprotein and total cholesterol values from the clinical trials were assessed. Study results indicate that rosuvastatin is not equivalent to other statins on a milligram-to-milligram basis.

CONCLUSIONS: Rosuvastatin appears to be at least 2 and 4 times as potent as atorvastatin and simvastatin, respectively, and at least 8 times as potent as pravastatin and lovastatin.

Key Words: HMG-CoA reductase inhibitors, rosuvastatin, statins, therapeutic interchange

Published Online, June 8, 2004. www.theannals.com, DOI 10.1345/aph.1D391




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.